Clinical Trials
76
58 active
Approvals
1
Total approvals
Agencies
1
Regulatory bodies
Founded
2009
Active, not recruiting
58
76.3%
Completed
7
9.2%
No Longer Available
1
1.3%
Suspended
1
1.3%
Terminated
9
11.8%
- Genelux Corporation has appointed Dr. Jason Litten as Chief Medical Officer effective January 2, 2026, to oversee clinical development and medical strategy for the company's oncolytic immunotherapy pipeline. - Dr. Litten brings over 20 years of biopharmaceutical experience, including leadership roles at Chimeric Therapeutics, Artiva Biotherapeutics, and Amgen, with expertise in Phase 1-4 clinical trials across multiple cancer types. - The appointment comes as Genelux advances Olvi-Vec through pivotal milestones, including ongoing Phase 3 trials in platinum-resistant ovarian cancer and Phase 2 trials in non-small-cell lung cancer. - Dr. Litten received a stock option grant for 275,000 shares as part of his compensation package, reflecting the company's confidence in his ability to advance their oncolytic vaccinia virus platform.
- The STAMPEDE trial found that adding metformin to standard care for 1,874 non-diabetic men with metastatic prostate cancer did not significantly improve overall survival (HR 0.91, 95% CI: 0.80-1.03, P = 0.15). - Metformin demonstrated significant metabolic benefits, with patients gaining less than half the weight of controls (2kg vs 4.4kg after two years) and showing improved cholesterol and blood sugar levels. - The drug was well-tolerated with diarrhea as the main side effect, and showed potential anti-cancer benefits in the highest-risk patient subgroup, though this finding was not statistically powered for definitive conclusions. - These metabolic improvements may help mitigate the adverse effects of androgen deprivation therapy and reduce cardiovascular risks in prostate cancer patients with extended survival.
